Modulating pharmacokinetics of an anti-interleukin-8 F(ab′) 2 by amine-specific PEGylation with preserved bioactivity

• Published in: International journal of pharmaceutics 2000-03, Vol.198 (1), p.83-95
• Main Authors: Koumenis, Iphigenia Leonidou, Shahrokh, Zahra, Leong, Steven, Hsei, Vanessa, Deforge, Laura, Zapata, Gerardo
• Format: Article
• Language: English
• Subjects: Anti-interleukin-8 antibody; Bioactivity; Biological and medical sciences; General pharmacology; Medical sciences; Pharmaceutical technology. Pharmaceutical industry; Pharmacokinetics; Pharmacology. Drug treatments; Polyethylene-glycolylation
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/S0378-5173(99)00458-5

By covalently attaching biocompatible polyethylene-glycol (PEG) groups to ε-amino groups of the F(ab′) 2 form of a humanized anti-interleukin-8 (anti-IL-8) antibody, we sought to decrease the in vivo clearance rate to give a potentially more clinically acceptable therapeutic. The in vivo clearance was modulated by changing the hydrodynamic size of the PEGylated antibody fragments. To achieve significant increases in the hydrodynamic size with minimal loss in bioactivity, high molecular weight linear or branched PEG molecules were used. Modification involved N-hydroxy-succinamide reaction of the PEGs with primary amines (lysines and/or the N-terminus) of the anti-IL-8 F(ab′) 2. The process of adding up to four linear 20 kDa PEG, or up to two branched 40kDa PEG, gave reproducible distribution of products. The components with uniform size (as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) were purified by a single-step ion-exchange high-performance liquid chromatography and showed no significant loss of biological activity in ligand binding and cell-based assays. Addition of a single branched 40 kDa PEG to a F(ab′) 2 (molecular weight (MW)=1.6 million Da) or up to two 40 kDa branched PEG (MW=1.9 million Da) increased the serum half-life to 48 h as compared with the unPEGylated F(ab′) 2 with a half-life of 8.5 h. This study shows that by attaching high molecular weight PEGs at a one or two sites, bioactive antibody fragments can be made reproducibly with sizes tailored to achieve the desired pharmacokinetics.